{"id":968704,"date":"2026-05-29T14:03:20","date_gmt":"2026-05-29T18:03:20","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/mannkind-to-host-conference-call-today-to-discuss-afrezza-pediatric-approval\/"},"modified":"2026-05-29T14:03:20","modified_gmt":"2026-05-29T18:03:20","slug":"mannkind-to-host-conference-call-today-to-discuss-afrezza-pediatric-approval","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/mannkind-to-host-conference-call-today-to-discuss-afrezza-pediatric-approval\/","title":{"rendered":"MannKind to Host Conference Call Today to Discuss Afrezza Pediatric Approval"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">DANBURY, Conn. and WESTLAKE VILLAGE, Calif., May  29, 2026  (GLOBE NEWSWIRE) &#8212; <strong>MannKind Corporation (Nasdaq: MNKD)<\/strong> announced today that management will host a conference call to discuss the recent FDA approval of Afrezza<sup>\u00ae<\/sup> for use in children and adolescents aged 6 and older living with diabetes at 4:30 p.m. Eastern on Friday, May 29, 2026. Presenting from the Company will be its Chief Executive Officer, Michael Castagna, PharmD and Kevin Kaiserman, MD, Senior Vice President, Therapeutic Area Head-Diabetes.<\/p>\n<p>Links to the live audio webcast of the presentation will be available on MannKind Corporation\u2019s website at:\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=j2M_Bh_wmog2Hx7nba_bfZlURA21KL87VLrt9t1wVI96QGxuqXvkX3w3lALtH2hRVP8e7_GORgmAlvNDPOk7XXenwNXoOKn-Lz0-WOptQ2IGDMKXdKJmu0dEkESUNcyH5euVA6ZRzMp3CvjyjYWb-53z3ARRpdbuzE1M2_MtCTsi1ZJP7GA-p0XF4kPlRKIRZykH3jryfiEIohDnSlLidNXBEZw0WK6efAZpd1VIOeko9ZTdzia0Zq_XwFacrQeSshawz_R2bCV0L8L1c7NflqEqPSJi3n5hcVD4LGgdj2EosRvj4EYn7z9XjIz7KSvvj2kLwHJUx5y4ESCc_Bt7_o1-mcicx5dGB3WqvOIGCebFLQBbRNRQQem7-Ppre9nWIbO7cXes1SY9_20wg0X0Jr3JIbra9ujeckodcuazHNrsKF4Zxggex6sv0rnhk1qTUSRVH9zaOL7p-Te3ZhDSeB4WJoDqERP99YCNIb3zkDp3zAQch7P5c4dxQhMfFoK3KXqjDyx0DN02VXd2E2RUHuc4vV8QYvJZrmLmrqQsUdrvHsKiily4cxXrHaWm5zti17mDqdUhAFq2vMVW27C8bC5x4hXaXti0DClQeEnqc0TQ6OKXZ9edlIN5GZfMo4aJ87VyW7uDD45REztaxplvJGdoy7ABvgmjpf9jsENxbpE9B36bjLW3NGku1j6TV14gEx_I-q79C8YE3768vKCf8JsV2enhRKWsx_ux5mFLiSZNHcr7HsBr3ax8U3csM3lZLKHsUZfmgVXRgVi0N27IAg==\" rel=\"nofollow\" target=\"_blank\"><strong>https:\/\/investors.mannkindcorp.com\/events-and-presentations<\/strong><\/a>. Recorded versions will also be available on the website for approximately 90 days following the conference.<\/p>\n<p>\n        <strong>About MannKind<\/strong><br \/>\n        <br \/>MannKind Corporation (Nasdaq: MNKD) is a biopharmaceutical company dedicated to transforming chronic disease care through innovative, patient-centric solutions. Focused on cardiometabolic and orphan lung diseases, we develop and commercialize treatments that address serious unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease.<\/p>\n<p>With deep expertise in drug-device combinations, MannKind aims to deliver therapies designed to fit seamlessly into daily life.<\/p>\n<p>Learn more at mannkindcorp.com.<\/p>\n<p>MANNKIND is a registered trademark of MannKind Corporation.<\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcyODk2NiM3NjI4MDk5IzIwMDgxMDc=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/MWY0YTYyZjYtOGRmOS00N2NiLWI2YWItMzZkMDIzYTNiYzA4LTEwMTk2ODAtMjAyNi0wNS0yOS1lbg==\/tiny\/MannKind.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\">\n<pre>MannKind Contacts:\r\nInvestor Relations\r\nKate Miranda\r\nEmail: ir@mnkd.com\r\n\r\nMedia Relations\r\nChristie Iacangelo\r\nEmail: media@mnkd.com<\/pre>\n<\/p><\/div>\n","protected":false},"excerpt":{"rendered":"<p>DANBURY, Conn. and WESTLAKE VILLAGE, Calif., May 29, 2026 (GLOBE NEWSWIRE) &#8212; MannKind Corporation (Nasdaq: MNKD) announced today that management will host a conference call to discuss the recent FDA approval of Afrezza\u00ae for use in children and adolescents aged 6 and older living with diabetes at 4:30 p.m. Eastern on Friday, May 29, 2026. Presenting from the Company will be its Chief Executive Officer, Michael Castagna, PharmD and Kevin Kaiserman, MD, Senior Vice President, Therapeutic Area Head-Diabetes. Links to the live audio webcast of the presentation will be available on MannKind Corporation\u2019s website at:\u00a0https:\/\/investors.mannkindcorp.com\/events-and-presentations. Recorded versions will also be available on the website for approximately 90 days following the conference. About MannKind MannKind Corporation (Nasdaq: MNKD) is a biopharmaceutical &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/mannkind-to-host-conference-call-today-to-discuss-afrezza-pediatric-approval\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;MannKind to Host Conference Call Today to Discuss Afrezza Pediatric Approval&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-968704","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.7 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>MannKind to Host Conference Call Today to Discuss Afrezza Pediatric Approval - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/mannkind-to-host-conference-call-today-to-discuss-afrezza-pediatric-approval\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"MannKind to Host Conference Call Today to Discuss Afrezza Pediatric Approval - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"DANBURY, Conn. and WESTLAKE VILLAGE, Calif., May 29, 2026 (GLOBE NEWSWIRE) &#8212; MannKind Corporation (Nasdaq: MNKD) announced today that management will host a conference call to discuss the recent FDA approval of Afrezza\u00ae for use in children and adolescents aged 6 and older living with diabetes at 4:30 p.m. Eastern on Friday, May 29, 2026. Presenting from the Company will be its Chief Executive Officer, Michael Castagna, PharmD and Kevin Kaiserman, MD, Senior Vice President, Therapeutic Area Head-Diabetes. Links to the live audio webcast of the presentation will be available on MannKind Corporation\u2019s website at:\u00a0https:\/\/investors.mannkindcorp.com\/events-and-presentations. Recorded versions will also be available on the website for approximately 90 days following the conference. About MannKind MannKind Corporation (Nasdaq: MNKD) is a biopharmaceutical &hellip; Continue reading &quot;MannKind to Host Conference Call Today to Discuss Afrezza Pediatric Approval&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/mannkind-to-host-conference-call-today-to-discuss-afrezza-pediatric-approval\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-05-29T18:03:20+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcyODk2NiM3NjI4MDk5IzIwMDgxMDc=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mannkind-to-host-conference-call-today-to-discuss-afrezza-pediatric-approval\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mannkind-to-host-conference-call-today-to-discuss-afrezza-pediatric-approval\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"MannKind to Host Conference Call Today to Discuss Afrezza Pediatric Approval\",\"datePublished\":\"2026-05-29T18:03:20+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mannkind-to-host-conference-call-today-to-discuss-afrezza-pediatric-approval\\\/\"},\"wordCount\":205,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mannkind-to-host-conference-call-today-to-discuss-afrezza-pediatric-approval\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTcyODk2NiM3NjI4MDk5IzIwMDgxMDc=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mannkind-to-host-conference-call-today-to-discuss-afrezza-pediatric-approval\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mannkind-to-host-conference-call-today-to-discuss-afrezza-pediatric-approval\\\/\",\"name\":\"MannKind to Host Conference Call Today to Discuss Afrezza Pediatric Approval - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mannkind-to-host-conference-call-today-to-discuss-afrezza-pediatric-approval\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mannkind-to-host-conference-call-today-to-discuss-afrezza-pediatric-approval\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTcyODk2NiM3NjI4MDk5IzIwMDgxMDc=\",\"datePublished\":\"2026-05-29T18:03:20+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mannkind-to-host-conference-call-today-to-discuss-afrezza-pediatric-approval\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mannkind-to-host-conference-call-today-to-discuss-afrezza-pediatric-approval\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mannkind-to-host-conference-call-today-to-discuss-afrezza-pediatric-approval\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTcyODk2NiM3NjI4MDk5IzIwMDgxMDc=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTcyODk2NiM3NjI4MDk5IzIwMDgxMDc=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mannkind-to-host-conference-call-today-to-discuss-afrezza-pediatric-approval\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"MannKind to Host Conference Call Today to Discuss Afrezza Pediatric Approval\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"MannKind to Host Conference Call Today to Discuss Afrezza Pediatric Approval - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/mannkind-to-host-conference-call-today-to-discuss-afrezza-pediatric-approval\/","og_locale":"en_US","og_type":"article","og_title":"MannKind to Host Conference Call Today to Discuss Afrezza Pediatric Approval - Market Newsdesk","og_description":"DANBURY, Conn. and WESTLAKE VILLAGE, Calif., May 29, 2026 (GLOBE NEWSWIRE) &#8212; MannKind Corporation (Nasdaq: MNKD) announced today that management will host a conference call to discuss the recent FDA approval of Afrezza\u00ae for use in children and adolescents aged 6 and older living with diabetes at 4:30 p.m. Eastern on Friday, May 29, 2026. Presenting from the Company will be its Chief Executive Officer, Michael Castagna, PharmD and Kevin Kaiserman, MD, Senior Vice President, Therapeutic Area Head-Diabetes. Links to the live audio webcast of the presentation will be available on MannKind Corporation\u2019s website at:\u00a0https:\/\/investors.mannkindcorp.com\/events-and-presentations. Recorded versions will also be available on the website for approximately 90 days following the conference. About MannKind MannKind Corporation (Nasdaq: MNKD) is a biopharmaceutical &hellip; Continue reading \"MannKind to Host Conference Call Today to Discuss Afrezza Pediatric Approval\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/mannkind-to-host-conference-call-today-to-discuss-afrezza-pediatric-approval\/","og_site_name":"Market Newsdesk","article_published_time":"2026-05-29T18:03:20+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcyODk2NiM3NjI4MDk5IzIwMDgxMDc=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mannkind-to-host-conference-call-today-to-discuss-afrezza-pediatric-approval\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mannkind-to-host-conference-call-today-to-discuss-afrezza-pediatric-approval\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"MannKind to Host Conference Call Today to Discuss Afrezza Pediatric Approval","datePublished":"2026-05-29T18:03:20+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mannkind-to-host-conference-call-today-to-discuss-afrezza-pediatric-approval\/"},"wordCount":205,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mannkind-to-host-conference-call-today-to-discuss-afrezza-pediatric-approval\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcyODk2NiM3NjI4MDk5IzIwMDgxMDc=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mannkind-to-host-conference-call-today-to-discuss-afrezza-pediatric-approval\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/mannkind-to-host-conference-call-today-to-discuss-afrezza-pediatric-approval\/","name":"MannKind to Host Conference Call Today to Discuss Afrezza Pediatric Approval - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mannkind-to-host-conference-call-today-to-discuss-afrezza-pediatric-approval\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mannkind-to-host-conference-call-today-to-discuss-afrezza-pediatric-approval\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcyODk2NiM3NjI4MDk5IzIwMDgxMDc=","datePublished":"2026-05-29T18:03:20+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mannkind-to-host-conference-call-today-to-discuss-afrezza-pediatric-approval\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/mannkind-to-host-conference-call-today-to-discuss-afrezza-pediatric-approval\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mannkind-to-host-conference-call-today-to-discuss-afrezza-pediatric-approval\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcyODk2NiM3NjI4MDk5IzIwMDgxMDc=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcyODk2NiM3NjI4MDk5IzIwMDgxMDc="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mannkind-to-host-conference-call-today-to-discuss-afrezza-pediatric-approval\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"MannKind to Host Conference Call Today to Discuss Afrezza Pediatric Approval"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/968704","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=968704"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/968704\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=968704"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=968704"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=968704"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}